Blog
RSS FeedPosted by Michael Wonder on 26 Jun 2023
New report from The King’s Fund shows the UK underperforming on treatable health conditions, says the ABPI
26 June 2023 - The King’s Fund today published their independent report commissioned by the ABPI comparing the NHS to other ...
Posted by Michael Wonder on 22 Jun 2023
Upadacitinib monohydrate for the treatment of patients with previously treated moderately to severely active Crohn’s disease
21 June 2023 - NICE has published final evidence-based recommendations on the use of upadacitinib monohydrate (Rinvoq) for the treatment ...
Posted by Michael Wonder on 21 Jun 2023
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
21 June 2023 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with lenvatinib ...
Posted by Michael Wonder on 21 Jun 2023
Darolutamide in combination with androgen deprivation therapy and docetaxel for the treatment of patients with hormone-sensitive metastatic prostate cancer
21 June 2023 - NICE has published final evidence-based recommendations on the use of darolutamide (Nubeqa) in combination with androgen ...
Posted by Michael Wonder on 21 Jun 2023
Dapagliflozin propanediol monohydrate for the treatment of adults with chronic heart failure with preserved or mildly reduced ejection fraction
21 June 2023 - NICE has published final evidence-based recommendations on the use of dapagliflozin propanediol monohydrate for the treatment ...
Posted by Michael Wonder on 20 Jun 2023
Cemiplimab for the treatment of patients with recurrent or metastatic cervical cancer
20 June 2023 - NICE is unable to make a recommendation on the use of cemiplimab (Libtayo) for the treatment of ...
Posted by Michael Wonder on 14 Jun 2023
Tixagevimab and cilgavimab for the prevention of COVID-19 disease
14 June 2023 - NICE has published final evidence-based recommendations on the use of tixagevimab and cilgavimab (Evusheld) for the ...
Posted by Michael Wonder on 14 Jun 2023
Dabrafenib mesylate and trametinib dimethyl sulphoxide for the treatment of patients with advanced BRAF V600 mutation positive non-small-cell lung cancer
14 June 2023 - NICE has published final evidence-based recommendations on the use of dabrafenib mesylate (Tafinlar) and trametinib dimethyl ...
Posted by Michael Wonder on 12 Jun 2023
One stop shop for AI and digital regulations for health and social care launched
12 June 2023 - A new online advice service to help the NHS and wider care system adopt and make ...
Posted by Michael Wonder on 09 Jun 2023
Considering tomorrow’s patients in today’s drug approvals
8 June 2023 - Responding to pressure from patients seeking access to promising new medicines, drug regulatory agencies have worked over ...
Posted by Michael Wonder on 07 Jun 2023
Bulevirtide acetate for the treatment of adults with chronic hepatitis D (final guidance)
7 June 2023 - NICE has published final evidence based recommendations on the use of bulevirtide (Hepcludex) for the treatment ...
Posted by Michael Wonder on 07 Jun 2023
New drugs pilot to tackle obesity and cut NHS waiting lists
7 June 2023 - More people living with obesity will have access to the newest and most effective obesity drugs to ...
Posted by Michael Wonder on 07 Jun 2023
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
7 June 2023 - NICE has published final evidence-based recommendations on the use of brexucabtagene autoleucel (Tecartus) for the treatment ...
Posted by Michael Wonder on 07 Jun 2023
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma
7 June 2023 - NICE has published evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the treatment of ...
Posted by Michael Wonder on 06 Jun 2023
Esketamine hydrochloride for the treatment of adults with major depressive disorder at imminent risk of suicide
6 June 2023 - NICE is unable to make a recommendation on the use of esketamine hydrochloride (Spravato) for the treatment ...